Evidence map›Paper›PMID 29176361›Full record

ReviewCurrent opinion in organ transplantation2018

Active targeted delivery of immune therapeutics to lymph nodes.

Baharak Bahmani, Ishaan Vohra, Nazila Kamaly, Reza Abdi

Abstract readReview
In one paragraph

Review in Current opinion in organ transplantation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Effect of physicochemical properties onActa pharmaceutica Sinica. B · 2021
    Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Baharak BahmaniRenal Division, Transplantation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Ishaan VohraRenal Division, Transplantation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Nazila KamalyBioinspired Nanomaterials Laboratory, Department of Micro and Nanotechnology, Technical University of Denmark, DTU Nanotech, Lyngby, Denmark.
Reza AbdiRenal Division, Transplantation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Funding

Organ Design and Engineering Training Program (ODET Program)T32EB016652 · NIBIB · BRIGHAM AND WOMEN'S HOSPITAL · PI BONVENTRE, JOSEPH VINCENT · 2014 to 2023
$3.5M
Protection of organ transplant from ischemia reperfusion injuriesR01AI126596 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI ABDI, REZA · 2016 to 2020
$2.6M
Developing novel biomarkers of renal transplant rejectionK24AI116925 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI ABDI, REZA · 2016 to 2023
$1.4M
SysCODE Interdisciplinary postdoctoral Training Grant (8 of 10)RL9RL9EB008539 · NIBIB · BRIGHAM AND WOMEN'S HOSPITAL · PI BONVENTRE, JOSEPH VINCENT · 2007 to 2011
$1.2M
NIAID NIH HHS K24 AI116925NIAID NIH HHS R01 AI126596NIBIB NIH HHS RL9 EB008539NIBIB NIH HHS T32 EB016652
6 · The paper itself

Abstract

purpose of reviewOrgan transplantation is a life-saving procedure and the only option for patients with end-organ failure. Immune therapeutics have been key to the success of organ transplantation. However, immune therapeutics are still unable to eliminate graft rejection and their toxicity has been implicated in poorer long-term transplant outcomes. Targeted nanodelivery has the potential to enhance not only the therapeutic index but also the bioavailability of the immune therapeutics. One of the key sites of immune therapeutics delivery is lymph node where the priming of immune cells occur. The focus of this review is on nanomedicine research to develop the targeted delivery of immune therapeutics to lymph nodes for controlling immune activation. RECENT

findingsAs nanomedicine creates its niche in clinical care, it provides novel immunotherapy platforms for transplant recipients. Draining lymph nodes are the primary loci of immune activation and represent a formidable site for delivery of wide variety of immune therapeutics. There have been relentless efforts to improve the properties of nanomedicines, to have in-depth knowledge of antigen and drug loading, and, finally, to explore various routes of passive and active targeted delivery to lymph nodes. SUMMARY: The application of nanotechnology principles in the delivery of immune therapeutics to the lymph node has created enormous excitement as a paradigm shifting approach that enables targeted delivery of a gamut of molecules to achieve a desired immune response. Therefore, innovative strategies that improve their efficacy while reducing their toxicity are among the highest unmet needs in transplantation.

Indexed as

NanomedicineAnimalsGraft RejectionHumansImmunologic FactorsLymph NodesImmunologic Factors

Identifiers

PMID29176361
PMCPMC7112238

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.